Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10277MR)

This product GTTS-WQ10277MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10277MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11400MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ4666MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ3804MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ10090MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ6691MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ403MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ15891MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ7900MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW